Detection and Clinical Significance of Peripheral Blood CTC, CA125, CA153, and CEA Levels in Patients with Ductal Carcinoma in situ

Abstract

Objective: To explore the detection and clinical significance of peripheral blood CTC, CA125, CA153, and CEA levels in patients with DCIS. Methods: 210 patients who received surgical treatment for breast cancer in our hospital from January 2019 to December 2022 were selected as the research subjects. According to the postoperative pathology, 100 cases were divided into breast cancer and 110 benign breast tumor groups. One hundred ten healthy patients undergoing physical examination during the same period were selected as the control group. CA153, CA125, and CEA levels were observed in the three groups. Results: The levels of CA153, CA125, and CEA in the breast cancer group were significantly higher than those in the benign breast tumor group and the control group (P < 0.05); the levels of CA153, CA125, and CEA in the benign breast tumor group were all higher than those in the control group, but the differences were not statistically significant; among the three tumor markers, CA153 has the highest sensitivity at 39.00%, CA125 has the second highest sensitivity at 18.00%, and CEA has the lowest sensitivity at 17.00%; The sensitivity of the two joint tests of CA153+CA125, CA153+CEA, and CA125+CEA for the diagnosis of breast cancer were 50.00%, 48.00%, and 26.00% respectively; the sensitivity of the three joint tests is the highest, reaching 53.00%, while the specificity of the joint tests was lower than the individual tests. Conclusion: Detection of peripheral blood CTC, CA125, CA153, and CEA levels has specific reference significance for the treatment and prognosis of DCIS patients.